David E. Neal

Q: What Schools Are Affiliated With David E. Neal

David E. Neal is affiliated with the following schools: University of California, Berkeley, University of Oxford, University of Newcastle , Dalhousie University, Stanford University, University of Surrey, University of Cambridge, Tulane University

David E. Neal's AcademicInfluence.com Rankings

David E. Neal

Computer Science

#3847

World Rank

#4043

Historical Rank

Computational Linguistics

#269

World Rank

#273

Historical Rank

Machine Learning

#576

World Rank

#583

Historical Rank

Artificial Intelligence

#778

World Rank

#790

Historical Rank

computer-science Degrees

Download Badge

Computer Science

David E. Neal's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is David E. Neal Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David E. Neal's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. (2017) (1959)
The Evolutionary History of Lethal Metastatic Prostate Cancer (2015) (1150)
Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. (2016) (887)
Screening for prostate cancer. (1998) (869)
Multiple newly identified loci associated with prostate cancer susceptibility (2008) (866)
CD133, a novel marker for human prostatic epithelial stem cells (2004) (768)
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis (2011) (552)
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array (2012) (550)
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer (2004) (515)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2018) (509)
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study (2009) (428)
Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers (2011) (420)
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer (2014) (416)
A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. (2000) (414)
Spatial genomic heterogeneity within localized, multifocal prostate cancer (2015) (401)
Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue (2015) (399)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Quality improvement report (2002) (369)
Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. (2001) (361)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer (2014) (358)
The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. (2013) (357)
Multiple loci with different cancer specificities within the 8q24 gene desert. (2008) (357)
Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer (2015) (322)
Multiple loci on 8q24 associated with prostate cancer susceptibility (2009) (316)
Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor* (2002) (299)
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study (2011) (295)
Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes (2014) (289)
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. (2014) (288)
Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers (2011) (285)
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer (1996) (285)
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. (2008) (269)
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial (2018) (265)
New androgen receptor genomic targets show an interaction with the ETS1 transcription factor (2007) (265)
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 (2011) (264)
Tip60 Is a Nuclear Hormone Receptor Coactivator* (1999) (263)
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility (2011) (261)
Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study (2002) (257)
Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study (2012) (247)
Structural basis for the nuclear import of the human androgen receptor (2008) (224)
Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. (2014) (219)
Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study (2015) (213)
Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development (2003) (208)
Mutational signatures of ionizing radiation in second malignancies (2016) (207)
Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway (2010) (203)
The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. (1998) (202)
Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. (2012) (196)
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion (2003) (194)
Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer (2001) (193)
A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer (2012) (185)
Genome-wide association study identifies new prostate cancer susceptibility loci. (2011) (183)
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation (2005) (178)
Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium (1998) (175)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
Evaluation of epidermal growth factor receptors in bladder tumours. (1987) (171)
Expression of mutant p53, c-erbB-2 and the epidermal growth factor receptor in transitional cell carcinoma of the human urinary bladder. (1991) (171)
Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. (2000) (170)
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets (2018) (169)
Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium (2008) (169)
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate. (1992) (168)
Long-term outcome related to epidermal growth factor receptor status in bladder cancer. (1995) (168)
RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. (2012) (165)
Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study (2015) (164)
Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target (2015) (164)
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. (2010) (164)
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (163)
Outcome of elective prostatectomy. (1989) (160)
It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. (2009) (155)
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening (2011) (155)
Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels (2010) (154)
Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial (2002) (154)
The effect of prostatectomy on symptom severity and quality of life. (1996) (153)
Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. (2010) (152)
FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease (1999) (149)
bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer. (1996) (148)
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. (2016) (146)
Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis (2010) (145)
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer (2017) (144)
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts (2018) (144)
Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. (2009) (144)
Bladder function in healthy volunteers: ambulatory monitoring and conventional urodynamic studies. (1994) (144)
Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. (1998) (136)
Prostate specific antigen and prostatitis I. Effect of prostatitis on serum psa in the human and nonhuman primate (1992) (133)
Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. (2003) (132)
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. (2013) (131)
C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. (1996) (129)
Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. (1997) (128)
A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. (2016) (127)
Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer (2002) (126)
Are diet–prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men (2003) (126)
A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk (2013) (125)
A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. (2014) (124)
Pentosan polysulfate sodium therapy for men with chronic pelvic pain syndrome: a multicenter, randomized, placebo controlled study. (2005) (123)
Use of terazosin in prostatodynia and validation of a symptom score questionnaire. (1994) (122)
Peptide growth factors in the prostate as mediators of stromal epithelial interaction. (1996) (119)
Bladder cancer--field versus clonal origin. (1992) (119)
Enhanced expression of EHMT2 is involved in the proliferation of cancer cells through negative regulation of SIAH1. (2011) (114)
Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer (2011) (112)
UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer (2009) (112)
Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium. (1999) (109)
Clean intermittent self-catheterisation in 172 adults. (1990) (108)
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis (2012) (106)
Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer (2018) (105)
Screening for prostate cancer. (2003) (104)
Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript (2011) (102)
Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. (1989) (102)
Association of Folate-Pathway Gene Polymorphisms with the Risk of Prostate Cancer: a Population-Based Nested Case-Control Study, Systematic Review, and Meta-analysis (2009) (102)
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group (2011) (101)
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression (2013) (100)
Exploring treatment preferences facilitated recruitment to randomized controlled trials (2011) (100)
Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. (2015) (99)
Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. (2004) (98)
Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer (2011) (98)
A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy (2015) (98)
Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. (2012) (96)
An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer (2003) (96)
Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. (2015) (95)
Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. (1996) (95)
Gene regulatory mechanisms underpinning prostate cancer susceptibility (2016) (94)
Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis (2008) (94)
Expression of Bcl‐2, Bax, and p53 in high‐grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation (1998) (93)
Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection (2014) (93)
Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. (2019) (93)
The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group (2010) (92)
The JmjC domain‐containing histone demethylase KDM3A is a positive regulator of the G1/S transition in cancer cells via transcriptional regulation of the HOXA1 gene (2012) (91)
Tip60 Is a Co-activator Specific for Class I Nuclear Hormone Receptors* (2001) (90)
Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67 (2001) (90)
The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine (2010) (89)
Deaths and complications following prostatectomy in 1400 men in the northern region of England. Northern Regional Prostate Audit Group. (1994) (89)
Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis (2014) (89)
p53 expression and clinical outcome in prostate cancer. (1993) (88)
Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. (2013) (88)
Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result (2010) (88)
Population‐based prostate‐specific antigen testing in the UK leads to a stage migration of prostate cancer (2009) (88)
Regulation of FGF8 expression by the androgen receptor in human prostate cancer (2002) (87)
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. (2019) (86)
A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. (2000) (86)
LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals (2009) (86)
Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer (2001) (86)
Peroxiredoxin-3 is overexpressed in prostate cancer and promotes cancer cell survival by protecting cells from oxidative stress (2013) (85)
Elevated levels of FOXA1 facilitate androgen receptor chromatin binding resulting in a CRPC-like phenotype (2013) (84)
Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer (2004) (84)
Keratinocyte growth factor expression in hormone insensitive prostate cancer (1997) (83)
Transcutaneous electrical nerve stimulation and temporary S3 neuromodulation in idiopathic detrusor instability. (1996) (83)
Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway. (2011) (83)
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants (2018) (83)
Symptoms, unmet needs, psychological well‐being and health status in survivors of prostate cancer: implications for redesigning follow‐up (2015) (83)
Complicated urinary tract infections. (2008) (82)
The National Prostatectomy Audit: the clinical management of patients during hospital admission. (1995) (82)
Comprehensive profiling and localisation of the matrix metalloproteinases in urothelial carcinoma (2006) (82)
Estrogen receptor beta in prostate cancer: friend or foe? (2014) (82)
Factors associated with suicide in patients with genitourinary malignancies (2015) (80)
Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. (2015) (79)
Homozygous deletion of gene for glutathione S-transferase M1 in bladder cancer. (1993) (78)
Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English cities (2011) (78)
Control of Human PIRH2 Protein Stability (2004) (78)
The National Prostatectomy Audit. (1997) (78)
The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium (2015) (78)
Epidermal growth factor receptor and bladder cancer: a review. (1992) (77)
Alterations in β‐catenin expression and localization in prostate cancer (2008) (77)
Associations of circulating 25‐hydroxyvitamin D with prostate cancer diagnosis, stage and grade (2012) (77)
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells (2015) (75)
Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. (2004) (75)
Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma. (2000) (74)
Over-expression of fibroblast growth factor-8 in human prostate cancer. (1996) (74)
c-erbB-2 amplification and identical p53 mutations in concomitant transitional carcinomas of renal pelvis and urinary bladder (1992) (74)
Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors (2005) (72)
Cytologic analysis of ureteral washings is informative in patients with grade 2 upper tract TCC considering endoscopic treatment. (2003) (72)
Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). (2003) (72)
DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: A feasibility study (2012) (71)
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans (2015) (71)
Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975–2004 (2008) (70)
Surgical margin length and location affect recurrence rates after robotic prostatectomy. (2015) (70)
Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer (2017) (70)
Clinical outcome and quality of life following enterocystoplasty for idiopathic detrusor instability and neurogenic bladder dysfunction. (1995) (70)
Nuclear LYRIC/AEG-1 interacts with PLZF and relieves PLZF-mediated repression (2009) (69)
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group (2012) (69)
aFGF immunoreactivity in prostate cancer and its co‐localization with bFGF and FGF8 (1999) (69)
Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review (2009) (69)
Shared heritability and functional enrichment across six solid cancers (2018) (67)
Identification of pathologically insignificant prostate cancer is not accurate in unscreened men (2014) (67)
The Histone Demethylase JMJD2B Plays an Essential Role in Human Carcinogenesis through Positive Regulation of Cyclin-Dependent Kinase 6 (2011) (67)
A prospective study of bladder function before and after sphincter-saving resections for low carcinoma of the rectum. (1981) (65)
P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. (1994) (65)
Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci (2015) (65)
Conventional urodynamics and ambulatory monitoring in the definition and management of bladder outflow obstruction. (1996) (64)
HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network (2014) (64)
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening (2009) (64)
Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors. (2009) (64)
The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer (2016) (63)
Ambulatory monitoring and electronic measurement of urinary leakage in the diagnosis of detrusor instability and incontinence. (1991) (63)
P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyperplasia. (1992) (62)
Unanswered questions in screening for prostate cancer. (2000) (62)
Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis. (1998) (62)
The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. (1999) (62)
Long-term monitoring of bladder pressure in chronic retention of urine: the relationship between detrusor activity and upper tract dilatation. (1988) (62)
The Scaffolding Protein RACK1 Interacts with Androgen Receptor and Promotes Cross-talk through a Protein Kinase C Signaling Pathway* (2003) (62)
Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk (2010) (61)
Association of diabetes mellitus with prostate cancer: Nested case–control study (Prostate testing for cancer and Treatment study) (2011) (61)
Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. (2010) (61)
Life course sun exposure and risk of prostate cancer: Population‐based nested case‐control study and meta‐analysis (2009) (60)
Androgen and oestrogen responsiveness of stromal cells derived from the human hyperplastic prostate: oestrogen regulation of the androgen receptor. (1994) (59)
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer (2009) (59)
Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey (2010) (59)
The potential value of microseminoprotein‐β as a prostate cancer biomarker and therapeutic target (2010) (58)
Screening for prostate cancer remains controversial (2009) (58)
Screen‐detected prostate cancer and the insulin‐like growth factor axis: Results of a population‐based case‐control study (2004) (58)
Neural network analysis of clinicopathological and molecular markers in bladder cancer. (2000) (58)
Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease? (2004) (57)
Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer (2008) (57)
Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy. (1991) (57)
Frequency of H-ras mutations in human bladder cancer detected by direct sequencing. (1994) (56)
Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. (2003) (56)
Prediction of individual genetic risk to prostate cancer using a polygenic score (2015) (56)
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. (1997) (56)
The histone methyltransferase Wolf–Hirschhorn syndrome candidate 1‐like 1 (WHSC1L1) is involved in human carcinogenesis (2013) (56)
Patient‐reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life (2016) (56)
Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. (2003) (55)
Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer (2014) (55)
Blood lipids and prostate cancer: a Mendelian randomization analysis (2016) (55)
Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. (2006) (54)
Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences (2014) (54)
Expression of c-erbB-2 protein product in bladder cancer. (1990) (54)
A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. (2015) (54)
A prospective randomized trial comparing transurethral resection of the prostate and laser therapy in men with chronic urinary retention: The CLasP study. (2000) (54)
A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH (2007) (53)
Ambulatory monitoring of bladder and detrusor pressure during natural filling. (1989) (53)
Androgen receptor signalling in the prostate (2000) (53)
Evaluating Genetic Risk for Prostate Cancer among Japanese and Latinos (2012) (53)
Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. (2012) (52)
Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. (2008) (52)
Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation (2016) (52)
Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study. (1998) (52)
Measuring the psychosocial impact of population‐based prostate‐specific antigen testing for prostate cancer in the UK (2006) (51)
The genomic evolution of human prostate cancer (2015) (50)
Screening for prostate cancer (2003) (50)
Measurement of voiding pressures on ambulatory monitoring: comparison with conventional cystometry. (1990) (49)
Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. (2001) (49)
Associations of lower urinary tract symptoms with prostate‐specific antigen levels, and screen‐detected localized and advanced prostate cancer: a case‐control study nested within the UK population‐based ProtecT (Prostate testing for cancer and Treatment) study (2008) (48)
Prognostic markers in bladder cancer (1996) (48)
Relationship between detrusor function and residual urine in men undergoing prostatectomy. (1987) (48)
Cell cycling in bladder carcinoma determined by monoclonal antibody Ki67. (1990) (47)
Ambulatory monitoring of bladder pressure in low compliance neurogenic bladder dysfunction. (1992) (46)
Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription. (2004) (46)
Symptoms, unmet needs, psychological well-being and health status in prostate cancer survivors (2015) (46)
Bowel dysfunction after bladder reconstruction. (1998) (46)
Transfection of S100A4 produces metastatic variants of an orthotopic model of bladder cancer. (2002) (46)
Associations of aspirin, nonsteroidal anti‐inflammatory drug and paracetamol use with PSA‐detected prostate cancer: Findings from a large, population‐based, case–control study (the ProtecT study) (2011) (45)
Relationship between voiding pressures, symptoms and urodynamic findings in 253 men undergoing prostatectomy. (1987) (45)
Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls (2016) (45)
Complications of ileal conduit diversion in adults with cancer followed up for at least five years. (1985) (44)
Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over (2008) (44)
Expression of retinoblastoma gene product and p53 protein in bladder carcinoma: correlation with Ki67 index. (1995) (44)
Decreasing suicide risk among patients with prostate cancer: Implications for depression, erectile dysfunction, and suicidal ideation screening. (2017) (44)
Basic science aspects of prostate cancer. (1997) (44)
The value of preserving the anal sphincter in operations for ulcerative colitis and polyposis: A review of 22 mucosal proctectomies (1981) (42)
High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers Identifies Mouse Double Minute 4 (MDM4) as an Amplification Target Exclusive of MDM2 and TP53 (2008) (42)
Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel (2019) (42)
Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. (1996) (42)
Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells (2001) (42)
The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals (2014) (41)
Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer (2007) (41)
Sex differences in oncogenic mutational processes (2019) (41)
Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study (2014) (40)
Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee (2016) (40)
Salt-Inducible Kinase 2 Regulates Mitotic Progression and Transcription in Prostate Cancer (2014) (40)
Epidermal growth factor receptor in human bladder cancer: a comparison of immunohistochemistry and ligand binding. (1989) (40)
EPIDERMAL GROWTH-FACTOR RECEPTOR - A MARKER OF EARLY RELAPSE IN BREAST-CANCER AND TUMOR STAGE PROGRESSION IN BLADDER-CANCER - INTERACTIONS WITH NEU (1989) (39)
A crossover randomized trial of transcutaneous electrical nerve stimulation and oxybutynin in patients with detrusor instability. (2001) (39)
TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. (1999) (39)
Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study (2013) (39)
p53 and p53-regulated genes in bladder cancer. (1998) (39)
Immunohistochemical detection of the epidermal growth factor receptor in paraffin‐embedded human tissues (1991) (39)
Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis (2014) (39)
Enhanced Expression of EHMT 2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH 11 , 2 (2014) (38)
Robotic-assisted laparoscopic prostatectomy (2009) (38)
Reducing mucus production after urinary reconstruction: a prospective randomized trial. (2001) (38)
Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer (2014) (38)
Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display (1997) (38)
A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom (2012) (38)
Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer (2012) (38)
Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. (2018) (38)
Prostatitis unplugged? Prostatic massage revisited. (1999) (37)
Cell relationship in a Wistar rat model of spontaneous prostatitis. (2001) (37)
Prostatectomy--an open or closed case. (1990) (37)
Chronic retention of urine. The relationship between upper tract dilatation and bladder pressure. (1986) (37)
HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer (2016) (37)
Testicular "Tumor" of the adrenogenital syndrome (1997) (37)
Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. (2017) (37)
Breast and prostate cancer in the relatives of men with prostate cancer. (1996) (37)
Filling and voiding pressures measured by ambulatory monitoring and conventional studies during natural and artificial bladder filling. (1991) (37)
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial (2017) (37)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2018) (37)
Increased mdr1 gene transcript levels in high-grade carcinoma of the bladder determined by quantitative PCR-based assay. (1994) (37)
Reproducibility of measurement of prostatic volume by ultrasound. Comparison of transrectal and transabdominal methods. (1988) (37)
Alcohol consumption and PSA-detected prostate cancer risk—A case-control nested in the ProtecT study (2012) (37)
Evaluation of Association of HNF1B Variants with Diverse Cancers: Collaborative Analysis of Data from 19 Genome-Wide Association Studies (2010) (37)
Differential C3NET reveals disease networks of direct physical interactions (2011) (36)
Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort (2016) (36)
Men with prostate cancer make positive dietary changes following diagnosis and treatment (2013) (36)
MT1-MMP regulates urothelial cell invasion via transcriptional regulation of Dickkopf-3 (2008) (36)
Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. (2013) (36)
Asporin is a stromally expressed marker associated with prostate cancer progression (2017) (36)
Treatment of carcinoma in situ with intravesical bacillus calmette-guerin without maintenance. 1 1 H. Barton Grossman, M.D (2002) (35)
The Royal College of Radiologists' Clinical Oncology Information Network. British Association of Urological Surgeons. Guidelines on the management of prostate cancer. (1999) (35)
The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer (2014) (35)
Pro-neural transcription factors as cancer markers (2008) (35)
The molecular pathology of urological malignancies (1997) (35)
Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group (2014) (35)
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations (2019) (35)
Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. (2001) (34)
c-jun oncogene expression in transitional cell carcinoma of the urinary bladder. (1994) (34)
Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group (2007) (34)
Tamm-Horsfall autoantibodies in interstitial cystitis. (1991) (34)
Adherence to Dietary and Lifestyle Recommendations and Prostate Cancer Risk in the Prostate Testing for Cancer and Treatment (ProtecT) Trial (2014) (34)
Focal air trapping in patients with HIV infection: CT evaluation and correlation with pulmonary function test results. (1999) (33)
N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 is overexpressed in cancer and promotes a pro-migratory and pro-metastatic phenotype (2014) (33)
Bronchial dilatation in patients with HIV infection: CT assessment and correlation with pulmonary function tests and findings at bronchoalveolar lavage. (1997) (33)
Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data (2017) (32)
Screening for prostate cancer in the UK (2001) (32)
Prostate cancer: to screen or not to screen? (2000) (32)
The scientific basis of urology (1999) (32)
Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade (2012) (32)
A role for neurotensin in bicalutamide resistant prostate cancer cells (2007) (32)
A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). (2006) (31)
Benign prostatic stromal cells are regulated by basic fibroblast growth factor and transforming growth factor-beta 1. (1996) (31)
Pelvic fibromatosis (desmoid)--treatment with steroids and tamoxifen. (1995) (30)
Genome-Wide Association Study of Prostate Cancer–Specific Survival (2015) (30)
Ambulatory monitoring of bladder pressures in patients with low compliance as a result of neurogenic bladder dysfunction. (1989) (30)
Genetic Variation in Prostate-Specific Antigen–Detected Prostate Cancer and the Effect of Control Selection on Genetic Association Studies (2014) (30)
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) (2016) (30)
Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy (2016) (30)
The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study (2010) (29)
Prostate specific antigen and prostatitis II. PSA production and release kinetics in vitro (1992) (29)
Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) (2014) (29)
Characterization of Escherichia coli strains causing urinary tract infections in patients with transposed intestinal segments. (2003) (29)
Surface localization of sacral foramina for neuromodulation of bladder function. An anatomical study. (1996) (29)
Comparison of long-term monitoring and standard cystometry in chronic retention of urine. (1986) (28)
Electromyographic abnormalities in the urethral and anal sphincters of women with idiopathic retention of urine. (1992) (28)
ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer (2018) (28)
Host defense mechanisms in urinary tract infections. (1999) (28)
Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy. (2012) (27)
International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy (2012) (27)
Urethral dilatation compared with cystoscopy alone in the treatment of women with recurrent frequency and dysuria. (1988) (27)
Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study (2011) (27)
Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study (2017) (27)
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer (2016) (27)
DESNT: A Poor Prognosis Category of Human Prostate Cancer. (2017) (27)
Transurethral prostatic resection or laser therapy for men with acute urinary retention: the ClasP randomized trial. (2001) (27)
Written consent about sexual function in men undergoing transurethral prostatectomy. (1994) (26)
Diagnosis of bladder cancer by immunocytochemical detection of minichromosome maintenance protein-2 in cells retrieved from urine (2012) (26)
Assessing the role of insulin‐like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels (2016) (26)
Mutation analysis of the MSMB gene in familial prostate cancer (2009) (26)
Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification (2015) (26)
Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries (2016) (26)
Effects of catheter size on urodynamic measurements in men undergoing elective prostatectomy. (1987) (26)
The effect of antimicrobial therapy on testicular aspirate flow cytometry. (1995) (26)
Urodynamic study of ileocystoplasty in the treatment of idiopathic detrusor instability. (1991) (26)
The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression (2020) (26)
Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. (2008) (26)
A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data (2019) (26)
Stage Shift in Psa-detected Prostate Cancers – Effect Modification by Gleason Score (2009) (26)
An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk (2020) (25)
Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? (2009) (25)
Bladder augmentation and replacement. Urodynamic and clinical review of 25 patients. (1991) (25)
A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer (2018) (25)
Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study (2016) (25)
No Evidence for Infection of UK Prostate Cancer Patients with XMRV, BK Virus, Trichomonas vaginalis or Human Papilloma Viruses (2012) (25)
Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer (2015) (25)
Year Outcomes after Monitoring , Surgery , or Radiotherapy for Localized Prostate Cancer (2016) (25)
Noradrenergic innervation of the human adrenal cortex as revealed by dopamine-beta-hydroxylase immunohistochemistry. (1992) (24)
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen (2020) (24)
Urodynamic investigation of the ileal conduit: upper tract dilatation and the effects of revision of the conduit. (1989) (24)
Misclassification of outcome in case–control studies: Methods for sensitivity analysis (2016) (24)
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer (2017) (24)
Identification of potential therapeutic targets in prostate cancer through a cross‐species approach (2018) (24)
High level expression of the multidrug resistance (MDR1) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens? (1996) (24)
Serum Insulin-Like Growth Factor-I Is Positively Associated with Serum Prostate-Specific Antigen in Middle-Aged Men without Evidence of Prostate Cancer (2004) (24)
Identification of new genetic risk factors for prostate cancer. (2009) (23)
Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the Prostate testing for cancer and Treatment study (2012) (23)
Analysis of Suicide Risk in Patients with Penile Cancer and Review of the Literature (2017) (23)
Late Imaging with [1-11C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET (2014) (23)
Mucin gene expression in human urothelium and in intestinal segments transposed into the urinary tract. (2000) (23)
Validation of the Hospital Episode Statistics Outpatient Dataset in England (2016) (23)
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study (2011) (23)
Alterations in expression of the multidrug resistance-associated protein (MRP) gene in high-grade transitional cell carcinoma of the bladder. (1996) (23)
Renin production after experimental extracorporeal shock wave lithotripsy: a primate model. (1991) (23)
Vitamin B12 malabsorption following bladder reconstruction or diversion with bowel segments (2002) (23)
Using Genetic Proxies for Lifecourse Sun Exposure to Assess the Causal Relationship of Sun Exposure with Circulating Vitamin D and Prostate Cancer Risk (2013) (23)
Downregulation of androgen receptor transcription by promoter g-quadruplex stabilization as a potential alternative treatment for castrate-resistant prostate cancer. (2013) (23)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer (2010) (22)
Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial (2015) (22)
Current status of linkage studies in hereditary prostate cancer (2000) (22)
The long term effects of proctectomy on bladder function in patients with inflammatory bowel disease (1982) (22)
A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. (2011) (22)
Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells (2014) (22)
Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. (2017) (22)
Androgen deprivation treatment in prostate cancer (2013) (21)
Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study (2009) (21)
Abnormalities in p53 and DNA content in transitional cell carcinoma of the bladder. (1994) (21)
Men’s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study (2014) (21)
Insulin‐like growth factor II and androgen receptor expression in the prostate (2000) (21)
Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research (2009) (21)
Mucus production after transposition of intestinal segments into the urinary tract (2004) (20)
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. (2020) (20)
Ryanodine receptors in human bladder smooth muscle (1999) (20)
Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas. (2001) (20)
A preliminary study of acetylcholinesterase-positive innervation in the human adrenal cortex. (1991) (20)
Adverse reactions to tiaprofenic acid mimicking interstitial cystitis (1994) (20)
CONSERVATIVE MANAGEMENT OF PROSTATE CANCER (1988) (20)
Properties of the 4‐Kallikrein Panel Outside the Diagnostic Gray Zone: Meta‐Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above (2017) (20)
Histochemical study of lectin binding in neoplastic and non-neoplastic urothelium. (1987) (20)
Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). (2018) (19)
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial (2007) (19)
Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study (2021) (19)
Transforming growth factor-â 1 upregulates p 15 , p 21 and p 27 and blocks cell cycling in G 1 in human prostate epithelium (1999) (19)
Cavernous tissue antibiotic levels in penile prosthesis surgery. (1992) (19)
Histological appearances of the nerves of the bladder in patients with denervation of the bladder after excision of the rectum. (1982) (19)
Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-Analysis (2014) (19)
A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. (2018) (19)
The accuracy of recording of occupational history in patients with bladder cancer. (1997) (19)
Associations of Lifestyle Factors and Anthropometric Measures with Repeat PSA Levels During Active Surveillance/Monitoring (2012) (19)
Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. (1997) (19)
Statistical problems with ‘optimal’ thresholds in studies of new prognostic factors in urology (2000) (18)
Screening for prostate cancer (1994) (18)
Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful? (2016) (18)
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen (2019) (18)
Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan (2020) (18)
Independence of HIF1a and androgen signaling pathways in prostate cancer (2019) (18)
Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer (2016) (18)
PTGS2–899G>C and prostate cancer risk: a population-based nested case–control study (ProtecT) and a systematic review with meta-analysis (2009) (18)
A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population (2016) (18)
Labeling and identification of LNCaP cell surface proteins: A pilot study (2007) (17)
Global assessment of network inference algorithms based on available literature of gene/ protein interactions (2013) (17)
Unilateral testicular microlithiasis associated with a seminoma (1997) (17)
Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. (2010) (17)
Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. (2009) (17)
Successful conservative management of nephrocolic fistula. (2001) (17)
PSA‐detected prostate cancer and the potential for dedifferentiation—estimating the proportion capable of progression (2011) (17)
Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial (2015) (17)
TENS: A treatment option for bladder dysfunction (2005) (17)
Transurethral prostate resection, noncontact laser therapy or conservative management in men with symptoms of benign prostatic enlargement? An economic evaluation. (2002) (17)
Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis (2016) (17)
Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue (2015) (16)
The bladder does not appear to have a dynamic secreted continuous mucous gel layer. (2005) (16)
AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma (2008) (16)
Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study (2018) (16)
Experimental prostatitis in nonhuman primates: II. Ascending acute prostatitis (1990) (16)
A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer (2018) (16)
Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. (2004) (16)
PSA testing for prostate cancer improves survival--but can we do better? (2010) (16)
Prostate‐specific antigen testing and prostate biopsy: are self‐reported lower urinary tract symptoms and health‐related quality of life associated with the decision to undergo these investigations? (2008) (15)
Reply to “Variation in KLK genes, prostate-specific antigen and risk of prostate cancer” (2008) (15)
Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer (2017) (15)
Adhesion of lymphocytes to bladder cancer cells: the role of the αEβ7 integrin (2002) (15)
Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. (2009) (15)
Pathogenesis of prostate cancer and hormone refractory prostate cancer (2007) (15)
The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers? (2011) (15)
Association between Prostinogen (KLK15) Genetic Variants and Prostate Cancer Risk and Aggressiveness in Australia and a Meta-Analysis of GWAS Data (2011) (15)
A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). (2010) (14)
Contractions in human detrusor smooth muscle induced by hypo-osmolar solutions. (1999) (14)
Very low PSA concentrations and deletions of the KLK3 gene. (2013) (14)
The association of diagnosis in the private or NHS sector on prostate cancer stage and treatment. (2012) (14)
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array (2016) (14)
SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design? (2008) (14)
The role of surgery in high‐risk localised prostate cancer (2012) (14)
Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer (2015) (14)
Delta‐aminolevulinic acid‐mediated photosensitization of prostate cell lines: Implication for photodynamic therapy of prostate cancer (1998) (14)
Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis (2012) (13)
The immunohistochemical detection of cripto‐1 in benign and malignant human bladder (1998) (13)
Serum keratinocyte growth factor measurement in patients with prostate cancer. (2000) (13)
Serum free prostate-specific antigen in the diagnosis of prostate cancer. (1997) (13)
Effects of multiple sequential extracorporeal shock wave treatments on renal function : a primate model (1991) (13)
Clean intermittent self-catheterization (2004) (13)
Non-invasive diagnosis (2007) (13)
Irreversible renal failure in men with outflow obstruction: is it a preventable disease? (1990) (13)
HES5 silencing is an early and recurrent change in prostate tumourigenesis (2015) (13)
Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy (2015) (13)
A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial (2017) (13)
Absence of long-term gonadotoxicity in primates receiving extracorporeal shock wave application. (1993) (13)
The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF‐I, IGF‐II, IGFBP‐1, IGFBP‐2 and IGFBP‐3 in a pooled analysis of 16,024 men from 22 studies (2019) (12)
Detrusor contraction strength in men undergoing prostatectomy (1993) (12)
Transrectal ultrasound appearances of schistosomal prostato-seminovesiculitis. (1996) (12)
Simultaneous Bilateral Extracorporeal Shock Wave Treatments of the Kidney in a Primate Model (1991) (12)
Evaluation and results of treatments for prostatism (2004) (12)
Haematogenous dissemination of prostate epithelial cells during surgery (1996) (12)
Urinary secretory immunoglobulin A and free secretory component in pyelonephritis. (1995) (12)
Nottingham health profile measurement in the assessment of clinical outcome after prostatectomy. Northern Regional Prostate Audit Group. (1995) (12)
The effects on pelvic visceral function of anal sphincter ablating and anal sphincter preserving operations for cancer of the lower part of the rectum and for benign colo-rectal disease. (1984) (12)
Molecular biological changes in bladder cancer. (1998) (12)
The effect of sample size on polygenic hazard models for prostate cancer (2019) (12)
Glutathione-S-Transferase π Expression in Transitional Cell Carcinoma of the Bladder (1993) (12)
Treatment of hypospadias: an update of current practice. (1998) (12)
Ultrasonography in the differentiation of complicated and uncomplicated acute pyelonephritis. (1990) (11)
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2019) (11)
Screening for prostate cancer. The case against. (2005) (11)
Adhesion of lymphocytes to bladder cancer cells: the role of the alpha(E)beta(7) integrin. (2002) (11)
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer (2020) (11)
Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel. (2016) (11)
Characteristics of the included studies (2012) (11)
PROSPECTIV—a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial (2014) (11)
Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer) (2015) (11)
The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor (2020) (11)
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer (2018) (11)
The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium (2015) (11)
The outcome of prostatectomy on chronic retention of urine. (1991) (11)
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer (2021) (11)
The role of the ileal conduit in the development of upper tract dilatation. (1985) (11)
Psychological distress and prostate specific antigen levels in men with and without prostate cancer (2009) (10)
Annals of the Royal College of Surgeons (2005) (10)
Ambulatory monitoring and electronic measurement of urinary leakage in the diagnosis of detrusor instability and incontinence (1992) (10)
Experimental prostatitis in nonhuman primates: I. Bacterial adherence in the urethra (1990) (10)
Erratum: Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 (The EMBO Journal (2012) 31 (1617) DOI:10.1038/emboj.2012.59) (2012) (10)
Fournier's gangrene (2006) (10)
Venous bypass and filtration during nephrectomy for renal carcinoma with tumour thrombus in the retrohepatic cava. (1991) (10)
The morbidity of transurethral resection of the prostate (1996) (10)
Gleason drift in the NIHR ProtecT study (2015) (10)
Fibroblast growth factor receptor‐2 mutation analysis in human prostate cancer (2000) (10)
Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study (2012) (10)
Methods for health economic evaluation (2012) (10)
The role of the nurse practitioner in a urology service. (1996) (10)
The Scientific Basis of Urology, Third Edition (2010) (10)
Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP) (2017) (9)
Improved needle placement technique in periurethral collagen injection. (1995) (9)
Continent urinary diversion using the Mitrofanoff principle. (1994) (9)
Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. (2018) (9)
P53 and ploidy assessed by flow cytometry in bladder washings. (1995) (9)
Effects of a new 5α reductase inhibitor (epristeride) on human prostate cell cultures (1997) (9)
Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring (2013) (9)
Can we accurately identify men with low risk prostate cancer? (2008) (9)
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array (2016) (9)
RAS pathways in prostate cancer - mediators of hormone resistance? (2010) (9)
Erratum: Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries (2017) (8)
Pediatric urolithiasis: review of research and current management (1994) (8)
The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297) (2004) (8)
Men’s experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study (2021) (8)
Seasonal variation in prostate‐specific antigen levels: a large cross‐sectional study of men in the UK (2011) (8)
Vasoactive intestinal peptide stimulation of human renal adenylate cyclase in vitro. (1990) (8)
Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta‐Analysis (2018) (8)
Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. (2011) (8)
Bilateral single ectopic ureters: diagnosis using transrectal ultrasound. (1993) (8)
Neural network analysis of prognostic markers in bladder cancer (1997) (8)
Is voided urine suitable for flow cytometric DNA analysis? (1991) (8)
Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro (1999) (8)
Interstitial cystitis: evaluation and related conditions. (2009) (7)
Neuromodulation in bladder dysfunction. (1998) (7)
A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections (2021) (7)
Comprehensive Textbook of Genitourinary Oncology (3rd edition) (2006) (7)
The feasibility and cost of a large multicentre audit of process and outcome of prostatectomy. (1995) (7)
Identification and Validation of Leucine-rich α-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification (2020) (7)
Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance. (2016) (7)
The ProtecT trial: evaluating the effectiveness of treatments for clinically localised prostate cancer (2009) (7)
Screening for bacteriuria in urological patients using reagent strips. (1992) (7)
Systemic chemotherapy for urothelial cancer in patients with ureteric obstruction. (1991) (7)
Attenuation of antibody response to acute pyelonephritis by treatment with antibiotics (1991) (7)
Outcome of elective prostatectomy: Authors' reply (1989) (7)
Changes in seminal fluid zinc during experimental prostatitis (2004) (6)
Neuromodulation of phasic detrusor activity by temporary S3 nerve-root stimulation (1997) (6)
Localized Prostate Cancer: Early Intervention or Expectant Therapy? (1997) (6)
The National Prostate Cancer Audit - introducing a new generation of cancer audit. (2014) (6)
Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. (2016) (6)
Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes (2016) (6)
Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium (2017) (6)
Prostate‐specific antigen patterns in US and European populations: comparison of six diverse cohorts (2016) (6)
Lower urinary tract symptoms and benign prostatic hyperplasia. (2004) (6)
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score (2021) (6)
The value of repeat serum PSA measurements in the detection of prostate cancer - Experience from the feasibility phase of the UK protect study (2006) (6)
Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial (2018) (6)
A self-administered patient questionnaire in the assessment of symptoms before and after prostatectomy. (1992) (6)
Successful preservation of potency in treatment of glans hyperemia following deep penile vein revascularization surgery. (1994) (5)
Evaluating best practice in informed consent discussions: a new method of evaluating information provision and patient understanding during trial recruitment consultations (2013) (5)
Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer (2016) (5)
Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study (2015) (5)
Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial (2020) (5)
Prevalence of benign prostatic hypertrophy (1991) (5)
Transrectal ultrasound guided needle electromyography of the urethral sphincter in males (1995) (5)
Tanagho bladder neck reconstruction in the treatment of adult incontinence. (1995) (5)
Paracrine regulation of talin mRNA expression by androgen in human prostate (1998) (5)
Regulation of the localisation and function of the oncogene LYRIC/AEG‐1 by ubiquitination at K486 and K491 (2014) (5)
10-Year Outcomes in Localized Prostate Cancer. (2017) (5)
Understanding factors influencing questionnaire response rates to maximise retention in a long term complex intervention trial (2011) (4)
Late renal failure due to prostatic outflow obstruction. (1989) (4)
In vivo transfer of an R-plasmid in a urinary tract infection model. (1989) (4)
A comparison of measurement of voiding pressures by ambulatory monitoring during natural filling and conventional cystometry (1989) (4)
Expression of Tip60, an androgen receptor co-activator, in prostate cancer (2001) (4)
KLK3 SNP–SNP interactions for prediction of prostate cancer aggressiveness (2021) (4)
The first national clinical audit of prostate cancer care (2013) (4)
Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial (2016) (4)
Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial (2016) (4)
Clean intermittent self catheterization (1993) (4)
Tumours in Urology (1994) (4)
Missing channels in two-colour microarray experiments: Combining single-channel and two-channel data (2007) (4)
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (4)
Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer. (2016) (4)
125I-vasoactive intestinal peptide binding in human kidney. (1991) (4)
The Molecular Biology of Bladder Cancer (2008) (4)
Supplementary file 1. (2015) (4)
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
Cripto-1 is a tumour specific marker of bladder cancer (1997) (4)
(2016). A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate risk. (2016) (4)
Outcome of endoscopic bladder transection. (1995) (4)
Cyclin D1 expression in transitional cell carcinoma (TCC) of the bladder: Correlation with WAF1, p53 and Ki67. (1998) (4)
Urethral recurrence after radical radiotherapy for bladder cancer. (2001) (4)
Supplementary file 3. (2014) (4)
HNF 1 B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer (2016) (4)
Prostate cancer: screening approaches. (2005) (4)
Laser ablation of urethral hair (1999) (4)
A Paratesticular Serous Borderline Tumor in a Pediatric Patient With Proteus Syndrome. (2015) (4)
Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial (2020) (3)
Factors associated with trial recruitment, preferences and treatments received were elucidated in a comprehensive-cohort study. (2019) (3)
Peroxisome Proliferator-activated Receptor a Is an Androgen-responsive Gene in Human Prostate and Is Highly Expressed in Prostatic Adenocarcinoma 1 (2000) (3)
AA9int: SNP interaction pattern search using non‐hierarchical additive model set (2018) (3)
Corrigendum to “Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study” [EBioMedicine 2 (9) (2015) 1133–1144] (2017) (3)
Prostate cancer detection in men aged 45-49 years in the UK ProtecT (Prostate testing for cancer and Treatment) trial (2006) (3)
Ethics of clinical trials from bayesian perspective: Randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer (2003) (3)
Abstract 2546: Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates withTERTexpression. (2013) (3)
A genetic risk score to guide age-specific, personalized prostate cancer screening (2016) (3)
Original Articles: Bladder Cancer (1995) (3)
Insulin-like growth factors (IGFs) and IGF-binding proteins in PSA-detected prostate cancer: a large population based case control study (ProtecT) (2011) (3)
Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2019) (3)
Immunological assessment of renal cancer patients as evaluated by the lymphocyte adherence inhibition test. (1986) (3)
Recruiters to randomised trials can be trained to facilitate recruitment and informed consent by exploring patients’ treatment preferences (2013) (3)
Mucin gene expression in normal urothelium and expression of MUC2 in transitional cell carcinoma of the bladder (1998) (3)
Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial (2017) (3)
TP 53 Accumulation Predicts Improved Survival in Patients Resistant to Systemic Cisplatin-based Chemotherapy for Muscle-invasive Bladder Cancer 1 (1999) (3)
Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study). (2022) (3)
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (3)
RECOVERY OF FUNCTION IN PATIENTS WITH DENERVATION OF THE BLADDER AFTER EXCISION OF THE RECTUM (1983) (3)
Super-selective arterial embolization for blunt trauma in the horseshoe kidney. (1998) (3)
Renal carcinoma with adjacent retroperitoneal fibrosis. (1989) (3)
Circulating insulin-like growth factors ( IGFs ) and IGF binding proteins ( IGFBPs ) in PSA-detected prostate cancer : the large case control study ProtecT (2011) (3)
Penile injury. (2001) (3)
PRESSURE AND FLOW IN ILEAL CONDUITS (1985) (3)
The effect of prostatectomy on symptom reduction and quality of life (1996) (2)
A model of the natural history of screen-detected prostate cancer (2006) (2)
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (2)
Evaluating the effectiveness of treatment for clinically localised prostate cancer (2004) (2)
Health Care Needs Assessment: Epidemiologically-based needs assessment reviews (2004) (2)
Targeting the pro‐survival side‐effects of androgen‐deprivation therapy in prostate cancer (2013) (2)
Molecular genetics and pathogenesis of renal cancer (2007) (2)
Comparison of Mutant and Wild-Type p53 Proteins in Merkel Cell Carcinoma (2000) (2)
Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium (2017) (2)
Southern Illinois University (SIU) sling-bone anchored semitendinosus. (2001) (2)
Men's experience of long term active monitoring (surveillance) within the ProtecT trial (2012) (2)
A PROSPECTIVE-STUDY OF THE EFFECT OF BLADDER DENERVATION ON MAXIMUM URETHRAL CLOSURE PRESSURE (MUCP) IN PATIENTS AFTER EXCISION OF THE RECTUM FOR CARCINOMA (1982) (2)
BLADDER FUNCTION AFTER EXCISION OF THE RECTUM FOR LOW RECTAL-CARCINOMA (1980) (2)
74 ASSOCIATIONS OF SEXUAL DYSFUNCTION WITH LOCALIZED AND ADVANCED PROSTATE CANCER: A CASE-CONTROL STUDY NESTED WITHIN THE UK POPULATION-BASED PROTECT (PROSTATE TESTING FOR CANCER AND TREATMENT) STUDY (2009) (2)
Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2019) (2)
Evaluation ofepidermal growth factor receptors inbladder tumours (1987) (2)
Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study) (2022) (2)
Ambulatory urodynamics. (1996) (2)
A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment. (2017) (2)
Anorchia masked by septo-optic dysplasia. (2012) (2)
Dr. Alexander Randall III and the Discovery of Randall's Plaques. (2020) (2)
Effect of vitamin D receptor gene on prostate cancer progression: genetic association study and meta-analysis (2008) (2)
Identification of a serum biomarker signature associated with metastatic prostate cancer (2021) (2)
Continent Catheterizable Vesicostomy: An Alternative Surgical Modality for Pediatric Patients With Large Bladder Capacity. (2016) (2)
Complications of Heal Conduit Diversion in Adults With Cancer Followed Up for at Least Five Years (1985) (2)
Limited additional lateral biopsies improve the diagnostic accuracy of transrectal ultrasound guided sextant prostate biopsy (2003) (2)
An evaluation of a selective prostate cancer screening program using family history as a supplementary screening tool to PSA: Results from the ProtecT trial (2017) (2)
Urinary diversion and bladder reconstruction/replacement using intestinal segments for intractable incontinence or following cystectomy. (2003) (2)
OR13,77 Insulin-like growth factors (IGFs) and IGF binding proteins in PSA-detected prostate cancer: a population-based case control study (2010) (2)
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. (2023) (2)
Supplementary file 2. (2014) (2)
Methods are changing rapidly (1995) (2)
961 THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER (2009) (2)
Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate CancerMortality The CAP Randomized Clinical Trial (2018) (2)
MDM2 and p53 immunoreactivity; independent predictors of stage progression in pTl bladder cancer (TCC) (1998) (2)
Author Correction: The evolutionary history of lethal metastatic prostate cancer (2020) (2)
Imaging , Diagnosis , Prognosis Engrailed-2 ( EN 2 ) : A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer (2011) (2)
Optimisation of bladder stromal culture on polyhipe (2002) (2)
Investigating the genetic relationship between Alzheimer’s disease and cancer using GWAS summary statistics (2017) (2)
TGF-ALPHA/EGF LEVELS IN BLADDER-CANCER AND THEIR RELATIONSHIP TO EGFR (1991) (1)
Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer (2011) (1)
Can oral antibiotic prohylaxis reduce the rate of infection following flexible cystoscopy (2003) (1)
EPIDERMAL GROWTH-FACTOR RECEPTORS IN HUMAN-BREAST, BLADDER AND LUNG-CANCER - CORRELATIONS WITH BIOLOGICAL BEHAVIOR (1986) (1)
Interstim Implants in the Pediatric Population (2008) (1)
Men’s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study (2014) (1)
Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial (2017) (1)
Focal changes in nerve, muscle and connective tissue density in human idiopathic bladder (1997) (1)
Do people who choose their treatment in a large randomised trial with parallel preference groups differ at baseline from those who agree to random treatment allocation? Results from the protect study (2015) (1)
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment (2023) (1)
Precision prostatectomy: reconciling functional and oncological outcomes (2019) (1)
Integrated DNA/RNA microarray profiling of hormone-refractory clinical prostate cancers and metastases indicates deregulation of several pathways, including androgen/AR, Hedgehog, MAPK and neuroactive ligand/receptor signalling (2006) (1)
Anabolic steroid abuse and male infertility. (1995) (1)
A randomized controlled feasibility trial of green tea and lycopene interventions in men at elevated risk of prostate cancer (ProDiet) (2017) (1)
Mucin gene expression in normal bladder and expression of MUC2 in TCC of the bladder (1998) (1)
Urinary Matrix Metalloproteinase-1 (MMP-1) and Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) in Bladder Cancer: a decreased MMP-1 (1999) (1)
Fibroblast growth factor receptor (FGFR) (1997) (1)
C-MYC induction of HES6 activates a distinct transcriptional network driving androgen insensitive prostate cancer (2011) (1)
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants (2018) (1)
Robert Benjamin Greenblatt and his many pursuits: an unlikely founder of the testosterone pellet. (2015) (1)
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2019) (1)
Additional SNPs improve the performance of a polygenic hazard score for prostate cancer (2020) (1)
Prostate Cancer UK: the Blue Skies Forum (2013) (1)
Prostate and Diet Study: Protocol v1.3 (2010) (1)
Case report: Conservative treatment of renal laceration in a patient with von Willebrand s disease (2020) (1)
RAISED BLOOD PRESSURE PREDICTS PROSTATE CANCER AND ELEVATED PSA IN A LARGE UNSELECTED POPULATION OF MEN PARTICIPATING IN THE PROTECT STUDY (2008) (1)
Effects of a new 5 alpha reductase inhibitor (epristeride) on human prostate cell cultures. (1997) (1)
Structure and Function of the Lower Urinary Tract (2010) (1)
Contractions induced by hypo-osmolar solutions in human detrusor muscle (1997) (1)
Regional variations in nerve density in the bladder wall of patients with idiopathic and neuropathic instability: identification of three discrete areas (1998) (1)
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) (1)
Dr. Hugh Hampton Young's Impact on Venereal Disease During World War I: The Chaste of American Soldiers. (2017) (1)
Abstract 2843: Caspase-8 gene SNPs in prostate cancer susceptibility: a replication study (2010) (1)
Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy (2015) (1)
FRII-01 THE IMPACT OF VENEREAL DISEASE DURING WORLD WAR I: HUGH HAMPTON YOUNG AND THE CHASTE OF AMERICAN SOLDIERS (2016) (1)
Prostatic relapse of an undifferentiated teratoma 24 years after orchidectomy (2015) (1)
Treatment of chronic prostatitis: an etiologicaly based approach. (1998) (1)
Erratum: High level expression of multidrug resistance (MDR1) gene in the normal bladder urothelium: A potential involvement in protection against carcinogens? (Carcinogenesis (1996) 17 (601-604)) (1996) (1)
Measurement of prostate specific antigen as screening test for prostate cancer. Paper gives misleadingly optimistic view. (1996) (1)
Phasic detrusor activity: Treatment by transcutaneous electrical nerve stimulation (1997) (1)
Adverse drug reactions in the urinary tract (1998) (1)
Evaluation of Dendritic Cell Immunogenicity After Activation and Chemical Fixation: A Mixed Lymphocyte Reaction Model (2002) (1)
Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2018) (1)
Expression ofmutantp53, c-erbB-2 andtheepidermal growth factor receptor intransitional cell carcinoma ofthehumanurinary bladder (1991) (1)
Clarification of NICE Guidance on Prostate Cancer (2009) (1)
Measurement of the insulin-like growth factor (IGF)-axis does not enhance the specificity of PSA-based prostate cancer screening. (2002) (1)
Abstract A123: Preclinical evaluation of dual mTOR inhibitor, AZD2014, in prostate cancer (2015) (1)
Pubertal development and prostate cancer risk (2018) (1)
Development of active monitoring system (2015) (1)
Supplementary File 4 (2014) (1)
Tumour suppressor genes and oncogenes (2004) (1)
re: Symptoms versus flow rates versus urodynamics in the selection of patients for prostatectomy. J. McLoughlin et al. Br. J. Urol., 66, 303-305, 1990. (1991) (1)
Evaluation of source data verification in a multicentre cancer trial (PROTECT) (2013) (1)
LYRIC, a novel modulator of Wnt/fO-catenin and androgen receptor signalling in prostate cancer (2008) (1)
A comparison between artificial neural networks and urologists' assessment of outcome in bladder cancer. I. Progression and recurrence in Ta/T1 tumours (1999) (1)
Screening for Bacteriuria in Urological Patients using Reagent Strips (1992) (1)
Differential expression of fibroblast growth factor receptor substrates in human malignancies (2002) (1)
Validation of BPH-related questionnaires in sixteen counties: Advancing age and decreased understanding (1998) (1)
DCE-MRI at 3T in Patients with Advanced Prostate Cancer Undergoing Androgen Deprivation Therapy (2010) (1)
637 THE PROTECT TRIAL - EVALUATING THE EFFECTIVENESS OF TREATMENTS FOR CLINICALLY LOCALISED PROSTATE CANCER AND ASSOCIATED MOLECULAR AND GENETIC EPIDEMIOLOGY STUDIES (2007) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Mucin gene expression in ileal segments transposed to the urinary tract (1998) (1)
Combined Waf1 and Tp53 Over-Expression Predict Improved Survival In Patients With Muscle-Invasive Bladder Cancer Treated By Radical Radiotherapy (1999) (1)
876 Comparative analyses of surgical modalities for the management of prostate cancer: A multi-institutional study of positive surgical margin rates on 22,403 patients operated on in the new millennium (2012) (1)
Fluconazole treatment of fungal UTIs in pediatric patients (1996) (1)
The Scientific Basis of Urology, Second Edition (2004) (1)
Ethical issues and molecular biology in urology. (1995) (1)
IGF-axis and screen-detected prostate cancer: A cross-sectional study (2003) (1)
SIGN: no. 85--management of transitional cell carcinoma of the bladder. (2006) (1)
Up-regulation of Flotillin 2 is associated with urothelial cell carcinoma progression (2008) (1)
Validation of The Hospital Episode Statistics Outpatient Dataset in England. (2014) (1)
O6-2.5 Alcohol and prostate cancer risk: a mendelian randomisation approach (2011) (1)
EXPRESSION OF P53, C-ERBB-2 AND THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN TRANSITIONAL CELL CARCINOMAS OF THE BLADDER (1991) (1)
Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study (2012) (1)
836 Hes6 drives a critical androgen receptor (AR) transcriptional program to induce castration resistant prostate cancer (CRPC) through activation of an E2F1-mediated cell cycle network (2014) (1)
MP9-10 FACTORS ASSOCIATED WITH SUICIDE IN PATIENTS WITH GENITOURINARY MALIGNANCIES (2015) (1)
Role of the androgen receptor in prostate cancer (2013) (1)
Responses to nitric oxide and cyclic nucleotides in isolated human detrusor smooth muscle (1998) (1)
Advances in Bladder Cancer (1994) (1)
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer (2017) (1)
The expression of heterotrimeric G-proteins in human bladder smooth muscle. (1998) (1)
Effects of a membrane trafficking protein on androgen response (2006) (0)
Effect of communicating phenotypic and genetic risk of coronary heart disease alongside web-based lifestyle advice: the INFORM Randomised (2019) (0)
Neural network analysis of clinicopathological and molecular prognostic markers in bladder cancer (1998) (0)
Functional reconstruction of the lower urinary tract and genitalia (1994) (0)
Risk of bias form (2012) (0)
Establishing dietary patterns of men before diagnosis of prostate cancer: developing dietary interventions for prevention (2010) (0)
332 Diagnosis of urothelial cell carcinoma by immunocytochemical detection of minichromosome maintenance protein 2 (MCM-2) in cells retrieved from urine (2012) (0)
So you want to train in urology. (1997) (0)
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer (2021) (0)
Pre-malignant Disease in the Prostate (2011) (0)
Longer Telomere length associates with Prostate Cancer (2014) (0)
Methodology article A new look towards BAC-based array C G H through a comprehensive comparison with oligo-based array C G H (2007) (0)
PO-0896: Radiotherapy quality assurance in the NIHR ProtecT trial (2015) (0)
Irish men under investigation for PCa. 0187: SINGLE CENTRE EXPERIENCE FROM THE ACCURACY OF CONVENTIONAL 1.5 T MAGNETIC RESONANCE IMAGING FOR THE DIAGNOSIS AND PRE-OPERATIVE STAGING OF PROSTATE CANCER (2015) (0)
Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer (2018) (0)
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates (2022) (0)
Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the Prostate testing for cancer and Treatment study (2012) (0)
Does the NMP22 bladder check test increase the accuracy of cystoscopy (2005) (0)
Shared heritability and functional enrichment across six solid cancers (2019) (0)
Growing Teratoma Syndrome: A Case of Mistaken Identity (2011) (0)
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (0)
Key questions in benign prostatic hyperplasia. (2003) (0)
THE ROLE OF ANDROGEN IN STROMAL-EPITHELIAL INTERACTIONS IN THE PROSTATE (1994) (0)
Mucin gene expression in human urothelium (2001) (0)
NCRI Cancer Conference 2010 (2010) (0)
Men with prostate cancer make positive dietary changes following diagnosis and treatment (2013) (0)
Low dose thalidomide in androgen independent prostate cancer (2002) (0)
Abstract 2782: Genetic susceptibility to prostate cancer progression and relationship with PSA level: Case-case study (2011) (0)
Abstract LB-176: The human androgen receptor regulates DNA damage response (DDR) in prostate cancer (2016) (0)
The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT study (2010) (0)
Staging of prostate cancer using three-dimensional TRUS imaging: A pilot study (1997) (0)
Transurethral prostatectomy (1994) (0)
The importance of agonist concentration in determining the mechanism of excitation-contraction coupling in human detrusor smooth muscle (1998) (0)
CAP Cause of Death Committee (2015). Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial: lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate (2015) (0)
Risk factors of age, family history of prostate cancer or a higher PSA level do not raise anxiety at prostate biopsy: a prospective cohort study (2009) (0)
AR-NLS:Importin-alpha complex (2008) (0)
1093 An international multi-center study examining re-classification rates of patients with prostate cancer suitable active surveillance whom underwent radical prostatectomy (2012) (0)
Issue Information (2019) (0)
NIHMS662581-supplement-Supplementary data (2016) (0)
4916 Absolute quantitation of metabolites in human prostate cancer biopsies by HR-MAS 1 H NMR spectroscopy (2013) (0)
Biological background: definition of high-risk bladder carcinoma: discussion (1997) (0)
British Medical Journal (1905) (0)
Classification of reported adverse effects using the Clavien–Dindo classification of surgical complications (2012) (0)
135 Psychological impact of PSA testing and biopsy using the impact of event scale (2013) (0)
Fine-mapping identifies multiple prostate cancer risk loci on 5p15 some associating with TERT expression (2013) (0)
Microarray expression profiling and array comparative genomic hybridisation of renal cell carcinoma (2005) (0)
Genome-wide differential gene network analysis R software and its application In LnCap prostate cancer (2017) (0)
NCRI Cancer Conference 2010, Liverpool, UK (2010) (0)
ERK5 expression in human prostate cancer (2002) (0)
Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2019) (0)
130 GINS proteins as candidate markers for urine-based cancer screening (2010) (0)
A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer (2018) (0)
Abstract B133: Regulation of the androgen receptor function by a metabolic kinase in prostate cancer. (2013) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2019) (0)
Abstract 4541: Metabolomic diagnosis of prostate cancer from urine (2012) (0)
Supplementary file 6. (2014) (0)
Prostate and Diet Study (2010) (0)
The single LXXLL motif in Tip60 mediates interaction with class I nuclear hormone receptors (2001) (0)
AR chromatin binding is reprogrammed in the absence of FOXA1 in ER- breast cancers (2019) (0)
Glutathione-S-transferase pi expression in transitional cell carcinoma of the bladder. (1993) (0)
Cultured bladder cell responses to hypo-osmolar solution; evidence for stretch activated channels? (1998) (0)
Whitington Supplementary Tables 2, 3 and 5–10 (2016) (0)
of sample on polygenic hazard models for prostate cancer. (2020) (0)
Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments (2016) (0)
The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK (2006) (0)
Are we overlooking stage a prostate cancer in patients treated for benign prostatic hyperplasia with medical or minimally invasive modalities? (1995) (0)
Investigating the role for c-myc and bHLH transcription factors in driving phenotypic versatility of cancer stem cells in castrate resistant prostate cancer (2010) (0)
Overexpression of FGF8B in advanced stage and high grade prostate cancer (2003) (0)
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]. (2020) (0)
769: Profiling and Localisation of the Matrix Metalloproteinases in Bladder Cancer (2005) (0)
PRACTICAL (2016). Blood lipids and prostate cancer: a Mendelian randomization analysis. (2016) (0)
Book reviewSurgical oncology, T.G. Allen-Mersh (Ed.), Chapman and Hall, Berlin (1996), p. 459, ISBN 0-412-48940-6 (1997) (0)
Abstract LB-003: Androgen-regulated proteome reveals a therapeutically relevant androgen receptor coactivator target in prostate cancer (2016) (0)
Supplementary file 5. (2014) (0)
Quantitation of human sprouty-2 (a novel inhibitor of fibroblast growth factor receptors) in human prostate cancer (2002) (0)
Blood lipids and prostate cancer: a Mendelian randomization analysis PRACTICAL consortium (2020) (0)
Transabdominal approach in radical nephrectomy for large renal tumours with IVC extension (2002) (0)
Matrix metalloproteinase expression and function in urothelial carcinoma (2005) (0)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2018) (0)
The Prostate 70 : 333 ^ 340 ( 2010 ) The Potential Value ofMicroseminoprotein-b as a ProstateCancerBiomarker andTherapeuticTarget (2010) (0)
Association analyses identify 31 new risk loci for colorectal cancer susceptibility (2019) (0)
Methods of the systematic review of clinical effectiveness (2012) (0)
The role of Mdm2 in androgen receptor regulation (2003) (0)
Female adult reconstructive urology. (1997) (0)
Expression profiling of chromatin remodelling genes in bladder cancers (2005) (0)
Addressing patient treatment preferences at trial recruitment (2011) (0)
Building a model for prostate-specific antigen during active monitoring (2015) (0)
NCRI (National Cancer Research Institute) Annual Conference, Birmingham, UK (2009) (0)
Towards derivation of a distinct signature permitting personalised treatment in prostate cancer (2013) (0)
PLOS ONE Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-analysis (2014) (0)
Disease mechanism, drug-target and biomarker prediction software: Application on prostate cancer and validation (2019) (0)
Biology of cancer and metastasis (2004) (0)
Health Care Needs Assessment: Benign Prostatic Hyperplasia (2004) (0)
Treatment for PSA screen-detected prostate cancer: what are the options? (2009) (0)
Infiltration of Normal and Cancerous Human Bladder by T Cells Expressing the αEβ7-Integrin (1999) (0)
Identification of peroxisome proliferator activated receptor alpha as an androgen responsive gene and its upregulation in prostatic carcinoma (1998) (0)
Debate Screening for prostate cancer (2005) (0)
976 A multi-institutional study comparing biochemical recurrence rates on 20,614 patients operated on in the new millennium (2012) (0)
DECREASING TREND IN STONE DISEASE: ARE MEN DOING SOMETHING RIGHT?: MP95‐09 (2017) (0)
Re: Penile Injury (2002) (0)
World Cancer Research Fund International Nutrition, Physical Activity and Cancer Prevention Conference (2010) (0)
POD-03.02: Interstim Implants in the Pediatric Population (2009) (0)
List of excluded studies: comparative studies in which number of patients for each baseline clinical stage was unclear (2012) (0)
Men with locally advanced prostate cancer excluded from the ProtecT Trial: early detection produces better outcomes (2015) (0)
Evaluation of the therapeutic potential of the EGFR tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer (2004) (0)
Transpubic Repair of Urethral Pathology in Women (2011) (0)
525: The Protect (Prostate Testing for Cancer and Treatment) Study: Advanced Cases Found Through a UK Screening Study (2006) (0)
FRII-13 NOT LACKING IN TESTICULAR FORTITUDE: THE EUNUCHS OF IMPERIAL CHINA (2015) (0)
MP-12.18 Transpubic Repair of Urethral Pathology in Women (2011) (0)
Molecular biology technology in intraoperative autologous transfusion during radical prostatectomy (1997) (0)
RANDOMISATION TO CLINICAL TRIALS OFFERS A SOLUTION TO TREATMENT CHOICE DILEMMA IN PROSTATE CANCER (2017) (0)
Single Center Deflux Experience (2011) (0)
CONSERVATIVE KIDNEY TRAUMA MANAGEMENT AND CONSERVATIVE POLITICS: HOW SIR WINSTON CHURCHILL'S PHYSICIANS MAY HAVE SAVED THE WESTERN WORLD: FRII‐09 (2017) (0)
THE HISTONE ACETYLTRANSFERASE TIP60 IS A CO-ACTIVATOR PROTEIN OF THE HUMAN ANDROGEN RECEPTOR PROTEIN (1999) (0)
Urinary diversion, scientific and clinical practice. G. D. webster and B. goldwasser (eds). 282 × 222 mm. Pp. 351. Illustrated. 1995. Oxford: Isis Medical Media. £69.95 (1996) (0)
Chemotherapy and muscle-invasive bladder cancer: Assessment of p53 immuno-reactivity (IR) as a predictor of response (1998) (0)
743 ASSOCIATION OF ANTHROPOMETRIC AND LIFESTYLE FACTORS WITH PROSTATE SPECIFIC ANTIGEN (PSA) TRAJECTORIES IN MEN WITH LOCALISED PROSTATE CANCER UNDERGOING ACTIVE MONITORING (2011) (0)
Profile study: Genetic prostate cancer risk stratification for targeted screening. (2013) (0)
P2-34 Association of anthropometric and lifestyle factors with prostate specific antigen (PSA) trajectories in men with localised prostate cancer undergoing active monitoring (2011) (0)
Cardiac & Smooth Muscle (0)
MP-17.02: Sacral Neuromodulation at a Single Center (2009) (0)
A Potential Immune Deviating Pathway that Protects Human Sperm and Aggressive Tumor Cells. (2010) (0)
BONE ANCHORED SACROCOLPOPEXY SAFETY AND EFFICACY (2008) (0)
Author ' s response to reviews Title : Key considerations for the experimental training and evaluation of cancer odour detection dogs : lessons learnt from a double-blind , controlled trial (2014) (0)
Molecular medicine and its impact on practice (2005) (0)
UTILIZATION OF RADIATION THERAPY FOR T2/T3 BLADDER UROTHELIAL CARCINOMA: A 25‐YEAR POPULATION‐BASED ANALYSIS: MP76‐20 (2017) (0)
FR01-14 RANDALL'S PLAQUES: A MYSTERY OF THE KIDNEY (2020) (0)
32nd Meeting of the Society of Clinical Trials, Vancouver, Canada (2011) (0)
Bladder cancer. (1996) (0)
The cell and cell division (2004) (0)
751OPREVALENCE OF HOXB13G84E GERMLINE MUTATION IN UK PROSTATE CANCER CASES; CORRELATION WITH TUMOUR CHARACTERISTICS AND OUTCOMES. (2014) (0)
IGF, PSA, glandular hyperplasia and cancer risk in the prostate (2003) (0)
Male Genital Tract Infections and Infertility (2007) (0)
Description of the care pathway (2012) (0)
Therapeutic fatty acid synthase inhibition can be monitored using 11C acetate pet in a xenograft model of prostate cancer (2013) (0)
LONG TERM RESULTS OF SACRAL NEUROMODULATION FOR VOIDING PROBLEMS IN THE PEDIATRIC POPULATION IN A SINGLE CENTER (2012) (0)
134: Malignancy in an Interstitial Cystitis Referral Population (2007) (0)
Hypoxia inducible factor 1 alpha confers androgen independence in prostate cancer (2018) (0)
Systems analysis of the renal transplant process (2004) (0)
Outcomes of sacral neuromodulation in children with dysfunctional elimination syndrome (2016) (0)
LONG-TERM EFFECTS OF PROCTOCOLECTOMY ON GENITOURINARY FUNCTION IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE (1981) (0)
Independence of HIF1a and androgen signaling pathways in prostate cancer (2020) (0)
Correction to ‘Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation’ (2021) (0)
A morphometric study of nerve, muscle and connective tissue in the 'unstable' bladder (1998) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
MEDIA AND INTERNET IMPACT ON RANDOMISATION RATES AND TREATMENT ACCEPTABILITY IN THE PROTECT STUDY (2008) (0)
935 Activation of HIF1α promotes androgen independent prostate cancer cell growth (2013) (0)
Patient information and the outcome of prostatectomy (1996) (0)
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer (2017) (0)
Involvement of TIP60 in androgen receptor signalling (2002) (0)
Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy (2016) (0)
Abstract 1191: Flotillin-2 overexpression is associated with an invasive urothelial cell carcinoma phenotype (2010) (0)
283 Similar expression to FGF (Sef) is an important determinant of the prostate cancer cells' ability to metastasise in vivo (2015) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
823 Transcriptional down-regulation of the androgen receptor by promoter G-quadruplex stabilisation; a potential alternative treatment in castrate-resistant prostate cancer (2013) (0)
551 D'AMICO RISK STRATIFICATION OUTPERFORMS PUBLISHED ACTIVE SURVEILLANCE SELECTION CRITERIA FROM THE USA AS A WAY TO IDENTIFY PATIENTS WITH INDOLENT PROSTATE CANCER IN A RELATIVELY UNSCREENED UK POPULATION (2013) (0)
National Cancer Research Institute Annual Conference, Liverpool, UK (2011) (0)
Short Report Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis (2019) (0)
Characterising the interaction between the human androgen receptor and the actin binding protein filamin (ABP 280) (1999) (0)
503 AN INTERNATIONAL MULTI-CENTRE STUDY EXAMINING DIAGNOSTIC CRITERIA FOR ACTIVE SURVEILLANCE IN MEN UNDERGOING RADICAL PROSTATECTOMY (2012) (0)
Surgery, reconstructive surgery (1992) (0)
Preclinical Evaluation of Dual mTOR Inhibitor, AZD2014, in Prostate Cancer (2015) (0)
PD60-02 DISCOVERY AND VALIDATION OF A NOVEL FLUID BIOMARKER FOR THE DIAGNOSIS AND RISK STRATIFICATION OF PROSTATE CANCER (2018) (0)
Chemotherapy And Muscle-Invasive Bladder Cancer: Tp53 And Mdm2 Immuno-Reactivity (Ir) As Predictors Of Response (1999) (0)
Treatment of detrusor instability with cordless transcutaneous electrical nerve stimulation (1997) (0)
Antigen presentation and induction of lymphocyte apoptosis by a transitional cell carcinoma line (1998) (0)
An introduction to cell biology (2004) (0)
TARGETING NOVEL NUCLEAR RECEPTORS WITH HISTONE DEACETYLASE INHIBITOR COMBINATION THERAPY IN BLADDER CANCER (2006) (0)
Costs of robotic equipment (2012) (0)
HIP1 mediates oncogenic transformation and cancer progression through STAT3 signalling (2020) (0)
Abstract 956: The evolutionary history of lethal metastatic prostate cancer (2015) (0)
OC-0126: A gene expression assay to predict the risk of distant metastases in localized prostate cancer (2017) (0)
The clam enterocystoplasty in the treatment of idiopathic detrusor instability (1992) (0)
MRC Clinical Trials Methodology Conference (2011) (0)
Comparison of prostate-specific antigen markers used to alert men to worsening prostate cancer (2015) (0)
G protein expression in human detrusor smooth muscle: their role in normal and unstable contractions (1998) (0)
Results of the systematic review of economic evaluations (2012) (0)
NCRI Cancer Conference 2008 (2008) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2019) (0)
Validation of the National Cancer Registration and Analysis Service prostate cancer registry with data from the CAP study (2016) (0)
RECTAL FUNCTION AFTER MUCOSAL PROCTECTOMY WITH ILEO-ANAL ANASTOMOSIS OR A PELVIC RESERVOIR FOR ULCERATIVE-COLITIS (1983) (0)
Evaluation of the yeast functional (FASAY) assay for detecting p53 mutations in bladder cancers (1998) (0)
95 Detection of asymptomatic locally advanced and high-risk prostate cancer through PSA testing: Clinical outcomes in men excluded from the ProtecT Trial (2016) (0)
Bladder reconstruction and urinary mucus (1997) (0)
Drugs in focus: 16. Finasteride (1995) (0)
Testing the accuracy of the prostate-specific antigen model in four separate cohorts (2015) (0)
Screen-detected prostate cancer and the insulin-like growth factor (IGF)-axis: Results of a case-control study (2002) (0)
Prostate Cancer DESNT : A Poor Prognosis Category of Human Prostate Cancer (2017) (0)
Human sprouty2 (a novel inhibitor of FGF receptor signalling) in human prostate cancer (2002) (0)
Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. (1), (2016) (0)
Abstract 1714: Transcriptional networks downstream of the AR identify clinically relevant prostate cancer targets (2010) (0)
1067 SIK2 is a novel secreted protein associated with a malignant phenotype in prostate cancer (2016) (0)
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets (2018) (0)
A comparison between artificial neural networks and urologists' assessment of outcome in bladder cancer. II. Survival in muscle-invasive (T2-T4) tumours (1999) (0)
Acquired venous disease of the lower urinary tract. (1990) (0)
Effective measurement of lower urinary tract symptoms including urinary incontinence, after surgery, radiotherapy or active monitoring treatment for localised prostate cancer (2017) (0)
RELATIONSHIPS BETWEEN GASTRIC-EMPTYING, INTESTINAL TRANSIT AND ABSORPTION AFTER PROCTOCOLECTOMY WITH AND WITHOUT ILEAL RESECTION (1983) (0)
The impact of urinary incontinence or erectile dysfunction on physical and mental health after treatment for localised prostate cancer (2017) (0)
Innovations in urologic surgery. R. Hohenfellner (ed.). 282 × 226 mm. Pp. 645. Illustrated. 1997. Oxford: Isis Medical Media. £150 (1997) (0)
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (0)
Investigating the prostate specific antigen, body mass index and age relationship: is an age–BMI-adjusted PSA model clinically useful? (2016) (0)
EVALUATION OF THE PRENYLTRANSFERASE INHIBITOR AZD3409 IN PRE-CLINICAL MODELS OF UROTHELIAL CARCINOMA (2006) (0)
A genetic hazard score to personalize prostate cancer screening, applied to population data (2019) (0)
Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study (2014) (0)
Mechanisms of Pathogenesis of Uro-Genital Cancers (2006) (0)
Abstract B52: Huntingtin interacting protein 1 (HIP1) mediates prostate carcinogenesis and progression through effects on signal transducers and activators of transcription (STATs) (2011) (0)
Clinical Cancer esearch an Cancer Biology Relationship between Prostate-Specific Antigen and state Cancer Risk : The Prostate Biopsy R laborative Group (2010) (0)
Abstract 2922: Androgen receptor driven transcription in a subtype of estrogen receptor negative breast cancer is controlled by FoxA1 (2012) (0)
Platinum Priority – Review – Prostate Cancer (2015) (0)
Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade (2012) (0)
EP-2298: Hypoxia inducible factor 1α confers androgen independence in prostate cancer (2018) (0)
Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2019) (0)
383 High risk upper tract transitional cell carcinoma: A multivariate analysis of risk factors (2004) (0)
Interferon-gamma inducible protein-10 (IP-10): quantitative immuno-localisation in bladder cancer (TCC) before and after intravesical Bacille Calmette-Guerin (BCG) (2002) (0)
Genome analysis AA 9 int : SNP Interaction Pattern Search Using Non-Hierarchical Additive Model Set (2018) (0)
Men’s and towards dietary prevention of a prostate cancer diagnosis: a qualitative study. (2014) (0)
1269 IMMUNOCYTOCHEMICAL DETECTION OF MINICHROMOSOME MAINTENANCE PROTEIN 2 (MCM-2) IN CELLS RETRIEVED FROM URINE CAN ACCURATELY DIAGNOSE UROTHELIAL CARCINOMA (2012) (0)
Prostate Epithelial Stem Cells (2004) (0)
Spatio-genomic heterogeneity within localized, multi-focal prostate cancer (2015) (0)
Surgical Oncology: Editorial (2002) (0)
Experiences and decision processes during PSA testing and prostate biopsy: A qualitative study (2007) (0)
597The value of repeat serum PSA measurements in the detection of prostate cancer — Experience from the UK protect study (2005) (0)
Detrusor contraction strength in men undergoing prostatectomy (0)
A preliminary studyofacetylcholinesterase-positive innervation inthehumanadrenal cortex (1991) (0)
Abstract# 2556: An investigation of the role of the caspase-8 gene in prostate and colon cancer susceptibility using a SNP-tagging approach (2009) (0)
OR4-4: The causal role of IGFs and IGFBPs in prostate cancer: a Mendelian randomization study (2014) (0)
043 Adjusting misclassification of outcome in case-control studies (2010) (0)
Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2018) (0)
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2019) (0)
Original Article The causal roles of vitamin B12 and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers? (2011) (0)
PD56-03 DETECTION OF PRIVATE CLONAL MUTATIONS IN LOCALISED PROSTATE CANCER FROM RARE MOLECULES OF CIRCULATING TUMOUR DNA (2018) (0)
A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom (2012) (0)
Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study (2012) (0)
Estimates of numbers of survivors and mean duration of survival (2012) (0)
Fibroblast growth factor-8 overexpression in prostate cancer predicts poor patient survival (1998) (0)
Results of the health economic evaluation (2012) (0)
Can a point-of-care proteomic assay increase the accuracy of cystoscopy? (2005) (0)
CLINICAL UROLOGY: Letters to the EditorRE: MUCIN GENE EXPRESSION IN HUMAN UROTHELIUM AND IN INTESTINAL SEGMENTS TRANSPOSED INTO THE URINARY TRACT (2001) (0)
1781 WHAT IS THE RISK OF HIGH RISK NON-MUSCLE INVASIVE BLADDER CANCER? AN ENGLISH CANCER NETWORK EXPERIENCE (2012) (0)
Clinical effectiveness of robotic compared with laparoscopic techniques (2012) (0)
The case against. (2005) (0)
prostatectomy . audit of process and outcome of The feasibility and cost of a large multicentre (0)
association studies cancer and the effect of control selection on genetic Genetic variation in protein specific antigen detected prostate (2014) (0)
ELECTRICALLY EVOKED ACTIVITY IN THE NORMAL EXTERNAL ANAL-SPHINCTER (1983) (0)
Examination of the urinary sediment in dipstick haematuria (1997) (0)
Abstract 3862: Identification of a novel genetic variant in theKLK3gene which predisposes to prostate cancer (2010) (0)
Soluble fibroblast growth factor receptor as a strategy to inhibit prostate tumorigenesis (2001) (0)
A Novel Mechanism of Tumour Immune Escape in Bladder Cancer (2002) (0)
Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan (2020) (0)
Description of the studies and data used for analysis (2015) (0)
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP Trial (2022) (0)
P 53 and bcI2 expression in TCC of the bladder (1998) (0)
Randomised controlled trials of active monitoring strategies (2015) (0)
Supplementary figure 6 Asim et al (2015) (0)
12 Benign Prostatic Hyperplasia (2004) (0)
Molecular Biology and Prostate Cancer (2013) (0)
Detailed risk of bias assessment for the included studies (2012) (0)
Qualitative study: clinicians’ and men’s views on the active monitoring system (2015) (0)
An investigation of apoptosis gene polymorphisms in prostate cancer (2006) (0)
General Biology of Cancer and Metastasis (2010) (0)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2018) (0)
Correlation between histological changes and urodynamic parameters in detrusor instability (1998) (0)
CHARACTERIZATION AND QUANTIFICATION OF AN EPIDERMAL GROWTH-FACTOR RECEPTOR (EGFR) IN HUMAN BLADDER-CANCER (1987) (0)
Localization of messenger RNA for matrix metalloproteinase-2 and -9, and tissue inhibitor of metalloproteinase-2 in human benign and malignant prostatic tissue by in situ hybridization (1997) (0)
A RANDOMIZED PLACEBO-CONTROLLED FEASIBILITY TRIAL OF DIETARY INTERVENTIONS FOR PROSTATE CANCER PREVENTION: PRODIET (2014) (0)
GA-binding protein alpha: an ETS family member with an important role in prostate cancer (2010) (0)
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2017) (0)
Abstract 2612: The PROFILE study; Germline genetic profiling: Correlation with targeted prostate cancer screening and treatment (2012) (0)
Source Data Verification in a multi-centre randomised controlled trial: the ProtecT study (2008) (0)
Abstract 1839: Alcohol intake and PSA levels in a European sample of middle-aged men invited for a PSA test (2010) (0)
Troglitazone does not sensitize the liver to insulin in the normal dog (1997) (0)
ThePROFILEFeasibilityStudy:TargetedScreeningofMenWithaFamily History of Prostate Cancer (2016) (0)
Role of Hes6 in castration-resistant prostate cancer (2014) (0)
Ileal Conduit Revisited (2003) (0)
Clinical significance of growth factor receptors in breast and bladder cancer (1986) (0)
Over-expression of MAP kinase kinase-5 (MEK5) in prostate cancer is related to presence of metastases and poor survival. (2002) (0)
Systematic review of active monitoring for prostate cancer (2015) (0)
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2019) (0)
942 The androgen receptor induces a distinct transcriptional program in castration resistant prostate cancer in man (2012) (0)
Identification and validation of a novel blood-based biomarker of aggressive prostate cancer (2017) (0)
Treating renal calculi. (1988) (0)
270: The Nuclear Import Receptor Importin α Binds to the Human Androgen Receptor Through a Region Encompassing its DNA Binding and Hinge Domains (2006) (0)
Developing dietary interventions for prostate cancer: systematic reviews and investigations of dietary change (2009) (0)
Ubiquitin and SUMO modification and intrinsic nuclear and nucleolar localisation signals target LYRIC to sub-nuclear compartments (2008) (0)
Tubio retrotransposition in cancer genomes Extensive transduction of nonrepetitive DNA mediated by L 1 (2014) (0)
992 GENETIC CORRECTION OF PSA LEVELS AND PROSTATE CANCER RISK MARKERS IMPROVE POSITIVE PREDICTIVE VALUE OF THE PSA TEST (2011) (0)
Density charts describing the distribution of total costs and quality-adjusted life-years for the cohort of modelled men for each analysis presented (2012) (0)
Characterization of flbroblast growth factor receptors in human prostate cancer (1997) (0)
The effect of sample size on polygenic hazard models for prostate cancer (2020) (0)
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1 (2013) (0)
Costs of laparoscopic equipment (2012) (0)
‘Once I knew there was a choice, I wanted to exercise that choice': using qualitative methods to understand why patients decline surgical trials (2013) (0)
Renal Cell Carcinoma, R. M. Bukowski and A. C. Novick (Ed.); Humana Press, Totowa, NJ, USA, 2000, (ISBN: 0-89603-781-9) (1999) (0)
Description of statistical methods used to model repeated measures of prostate-specific antigen (2015) (0)
Expression profiling of chromatin remodelling genes in bladder and renal cancers (2004) (0)
MP39-09 PROPERTIES OF THE FOUR KALLIKREIN PANEL FOR PREDICTION OF PROSTATE BIOPSY OUTCOME IN MEN WITH HIGH PSA (10-25 NG /ML) (2016) (0)
Essays for the Urologist Urological oncology—Dilemmas and developments (1992) (0)
Down-regulation of MT1-MMP leads to inhibition of invasion and increased expression of anti-migratory gene in urothelial carcinoma cell line (2007) (0)
833 Monitoring the effects of therapeutic fatty acid synthase inhibition in prostate canecr using 11C acetate PET (2013) (0)
Qualitative study: clinicians’ and men’s views on current active surveillance practices (2015) (0)
Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer (2015) (0)
Prostate cancer IV (2003) (0)
Cyclin A expression in bladder cancer: Correlation with Ki67 index (1998) (0)
Circulating vitamin D and risk of breast and prostate cancer: a Mendelian randomization study (2018) (0)
624 The combination of urine Pap cytology with immunocytochemical detection of minichromosome maintenance protein 2 (MCM-2) in patients with visible haematuria identifies most bladder cancers (2014) (0)
Validation of a modelling approach to estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence Modelling effectiveness of cancer screening (2012) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David E. Neal?

David E. Neal is affiliated with the following schools:

David E. Neal's Academic­Influence.com Rankings

David E. Neal's Degrees

Similar Degrees You Can Earn

Why Is David E. Neal Influential?

David E. Neal's Published Works

Published Works

What Schools Are Affiliated With David E. Neal?

David E. Neal's AcademicInfluence.com Rankings